Abstract
The pathophysiological relationship between scleroderma and malignancy remains poorly understood. Although some previous studies have demonstrated an increased malignancy risk in patients with scleroderma, others have been inconclusive. We aimed to determine if patients with scleroderma had an increased risk of malignancy compared to an age- and sex-matched local South West England population, and if there were any important differences between scleroderma patients with and without malignancy. Methods of this study are as follows. Notes were obtained on all local scleroderma patients (n = 68) locally, and those diagnosed with malignancy verified by contacting each patient’s general practitioner. Expected malignancy figures were obtained from age- and sex-stratified regional prevalence data provided by the South West Cancer Intelligence Service registry. Among the patients, 22.1% with scleroderma were identified with concurrent malignancy. Affected sites were of the breast (n = 5), haematological system (n = 5), skin (n = 4), and unknown primary (n = 1). Overall, malignancy risk was found to be increased in scleroderma (RR = 3.15, 95% CI 1.77–5.20, p = 0.01). In particular, this risk was the highest for haematological malignancies (RR = 18.5, 95% CI 6–43, p = 0.03), especially for non-Hodgkin’s lymphoma (RR = 25.8, 95% CI 5–75, p = 0.10). The majority of patients (86.7%) developed malignancy after the onset of scleroderma (mean = 6.9 years). Age of >70 and patients with limited scleroderma were significant risk factors for a patient with scleroderma to have a concurrent malignancy; however, no increased risk was found in patients with any particular pattern of organ involvement, cytotoxic usage or serology. To conclude, in this small patient cohort, we have found that scleroderma is associated with an increased risk of malignancy. This risk is statistically significant in patients with limited scleroderma. Patients who are elderly and those with limited disease should be closely scrutinized at follow-up appointments.
Similar content being viewed by others
References
Sigurgeirsson B, Lindelöf B, Edhag O et al (1992) Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 326:363–367
Lazarus MN, Robinson D, Mak V et al (2006) Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology 45(8):1012–1015
Gayed M, Bernatsky S, Ramsey-Goldman R et al (2009) Lupus and cancer. Lupus 18(6):479–485
Smitten AL, Simon TA, Hochberg MC et al (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45. doi:10.1186/ar2404
Zatuchni J, Campbell WN, Zarafonetis CJ (1953) Pulmonary fibrosis and terminal bronchiolar (alveolar-cell) carcinoma in scleroderma. Cancer 6(6):1147–1158
Pearson JE, Silman AJ (2003) Risk of cancer in patients with scleroderma. Ann Rheum Dis 62:697–699
Rosenthal AK, McLaughlin JK, Gridley G et al (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76:910–914
Hill CL, Nguyen AM, Roder D et al (2003) Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62(8):728–731
Chatterjee S, Dombi GW, Severson RK et al (2005) Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52(8):2415–2424
Duncan SC, Winkelmann RK (1979) Cancer and scleroderma. Arch Dermatol 115:950–955
LeRoy EC, Black C, Fleischmajer R (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205
Uitenbroek, Daan G (1997) Binomial. SISA. http://www.quantitativeskills.com/sisa/distributions/binomial.htm. (1 Jan. 2004)
Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750–755
Grady WM (2005) Transforming growth factor-β, Smads and cancer. Clin Cancer Res 11:3151–3154
Dong M, Blobe GC (2006) Role of transforming growth factor-beta in haematologic malignancies. Blood 107(12):4589–4596
Kretzschmar M (2000) Transforming growth factor-β and breast cancer: transforming growth factor-β/SMAD signaling defects and cancer. Breast Cancer Res 2(2):107–115
Radis CD et al (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38:1120–1127
Abu-Shakra M et al (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441
Wenzel J (2002) Scleroderma and malignancy: mechanisms of interrelationship. Eur J Dermatol 12(3):296–300
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siau, K., Laversuch, C.J., Creamer, P. et al. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 31, 641–645 (2011). https://doi.org/10.1007/s00296-009-1348-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1348-y